Sanofi Reports meta-analysis Data for Crizotinib in Crohn's disease

Sanofi today announced meta-analysis results for crizotinib in patients with Crohn's disease. The study demonstrated that crizotinib demonstrates sustained efficacy compared to standard of care or placebo. These results provide important insights into the treatment of Crohn's disease and support the continued development of crizotinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.